Evicenter
P&T meetings

Emiltatug ledadotin (Emi-Le)

Adenoid cystic carcinoma with solid histology or high-grade transformation

Also known as XMT-1660
Manufacturer
Servier
Regulatory submission
Not announced
Launch
Not announced
Last updated
125 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care

Radiotherapy

3 evidence topics · 3 sources

ESMO-EURACAN guideline: re-irradiation and palliative radiotherapy

“Local recurrence within the high-dose area following initial RT remains a challenge. When surgery is not an option, systemic treatments (either ChT or targeted agents) offer limited benefit with very moderate overall response rates and are therefore rarely successful in alleviating local symptoms.” (opens the source at this quote in a new tab)

“Based on these studies, re-irradiation with C12 appears feasible with response rates of around 60% and moderate toxicities in heavily pre-treated patients; however, C12 has limited availability in Europe.” (opens the source at this quote in a new tab)

“For patients with AdCC or AcCC and a WHO performance status score of 0-1, an even more prolonged RT schedule for palliation of locoregional disease or symptomatic distant metastases might be considered.” (opens the source at this quote in a new tab)

“Re-irradiation with C12 can be considered [IV, B]. Evidence is lacking to support the added value of proton treatment [V, C].” (opens the source at this quote in a new tab)

“There is currently no evidence to support the combination of re-irradiation and ChT for primary treatment of SGC [IV, C].” (opens the source at this quote in a new tab)

ASCO guideline: radiotherapy for patients who are not surgical candidates

“Radiotherapy should be offered to patients with SGM who are not candidates for surgical resection (because of extent of disease or medical comorbidity).” (opens the source at this quote in a new tab)

“Particle therapy, including proton, neutron, and carbon ion therapy, may be used for patients with SGM; there are no indications for the use of heavy particle therapy over photon or electron therapy.” (opens the source at this quote in a new tab)

Stereotactic body radiotherapy for oligometastatic ACC: SOLAR trial
FieldRegistry record
Brief title“Stereotactic Body Radiotherapy (SBRT) for Early Treatment of Oligometastatic Adenoid Cystic Carcinoma: The SOLAR Trial”
Brief summary“The aim of this study is to learn whether the early initiation of a specialized and focused type of radiation called stereotactic body radiation therapy (SBRT) will impact the progression of advanced adenoid cystic carcinoma, quality of life, and overall survival.”
Cohort 1 eligibility“One to five detectable sites of metastatic disease at any organ or site (including bone and CNS involvement)”
Overall status“Recruiting”